title: Efficacy of 6-mercaptopurine treatment after azathioprine hypersensitivity in inflammatory bowel disease.
abstract: OBJECTIVE
  To investigate the efficacy of 6-mercaptopurine (6-MP) in cases of azathioprine (AZA) hypersensitivity in patients with inflammatory bowel disease.
  
  
  METHODS
  Twenty nine previously confirmed Crohn's disease (CD) (n = 14) and ulcerative colitis (UC) (n = 15) patients with a known previous (AZA) hypersensitivity reaction were studied prospectively. The 6-MP doses were gradually increased from 0.5 up to 1.0-1.5 mg/kg per day. Clinical activity indicies (CDAI/CAI), laboratory variables and daily doses of oral 5-ASA, corticosteroids, and 6-MP were assessed before and in the first, sixth and twelfth months of treatment.
  
  
  RESULTS
  In 9 patients, 6-MP was withdrawn in the first 2 wk due to an early hypersensitivity reaction. Medication was ineffective within 6 mo in 6 CD patients, and myelotoxic reaction was observed in two. Data were evaluated at the end of the sixth month in 12 (8 UC, 4 CD) patients, and after the first year in 9 (6 UC, 3 CD) patients. CDAI decreased transiently at the end of the sixth month, but no significant changes were observed in the CDAI or the CAI values at the end of the year. Leukocyte counts (P = 0.01), CRP (P = 0.02), and serum iron (P = 0.05) values indicated decreased inflammatory reactions, especially in the UC patients at the end of the year, making the possibility to taper oral steroid doses.
  
  
  CONCLUSIONS
  About one-third of the previously AZA-intolerant patients showed adverse effects on taking 6MP. In our series, 20 patients tolerated 6MP, but it was ineffective in 8 CD cases, and valuable mainly in ulcerative colitis patients.
authors.affiliation: First Department of Medicine, Faculty of Medicine, University of Szeged, Szeged, Hungary. agyferi@in1st.szote.u-szeged.hu
authors.forename: Ferenc
authors.initials: F
authors.lastname: Nagy
authors.forename: Tamas
authors.initials: T
authors.lastname: Molnar
authors.forename: Zoltan
authors.initials: Z
authors.lastname: Szepes
authors.forename: Klaudia
authors.initials: K
authors.lastname: Farkas
authors.forename: Tibor
authors.initials: T
authors.lastname: Nyari
authors.forename: Janos
authors.initials: J
authors.lastname: Lonovics
mesh_terms: D000305:Adrenal Cortex Hormones / Q000494:pharmacology; D000328:Adult; D000368:Aged; D001379:Azathioprine / Q000494:pharmacology*; D003093:Colitis, Ulcerative / Q000188:drug therapy; D003424:Crohn Disease / Q000188:drug therapy; D004342:Drug Hypersensitivity; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy* / Q000473:pathology*; D008297:Male; D015122:Mercaptopurine / Q000494:pharmacology*; D008875:Middle Aged; D013256:Steroids / Q000494:pharmacology
chemical_list: D000305:Adrenal Cortex Hormones; D007166:Immunosuppressive Agents; D013256:Steroids; D015122:Mercaptopurine; D001379:Azathioprine